However, neoantigen-MAGE-A-specific CD8+ T cells are present in about 50% of the patients, whereas neoantigen-(NY-ESO-1 and Glypican-3)-specific circulating CD8+ T cells are present in less than 15% of HCC cases [79]. This evidence concerns the gene CD8A and hepatocellular carcinoma.